



INTERCEPTOR

INTERCEPTION OF ORAL CANCER DEVELOPMENT

COST Action CA21140



OPMDay

PROGRAM

2nd EDITION



30-31 AUGUST 2023



UNIVERSITY OF ANTWERP - BELGIUM

SCAN ME



FOR MORE INFORMATION ON THE COST ACTION

<https://www.cost.eu/actions/CA21140/>

UZA'



Funded by
the European Union

cost
EUROPEAN COOPERATION
IN SCIENCE & TECHNOLOGY

GENERAL INFORMATION

VENUE

University of Antwerp - Stadscampus
Klooster van de Grauwzusters
Building S
Lange Sint-Annastraat 7
2000 Antwerpen - Belgium



<https://www.uantwerpen.be/en/about-uantwerp/campuses/catering-conventionhalls/convention-halls/klooster-grauwzusters/>

TRAVEL INFO

By Train

You can plan your trip with the **Belgian train route planner** : <https://www.belgiantrain.be/en>
You can also travel to Antwerp with international bus lines such as Eurolines or Flixbus.

Traveling from the rail station to the campus:

Antwerpen Centraal to Stadscampus: around 15 min. by walk or 5 min. by bike

By Air

There are several airports you can choose from to reach Antwerp, including but not limited to:

Brussels Airport (Zaventem Airport)

Brussels Airport is the most frequently used gateway to Antwerp.

From Brussels Airport, you can travel to Antwerp by train (time schedules and fares are available on the website of the Belgian Railways), by bus with Airport Express or by taxi.

From other Airports, please look at this link:

<https://www.uantwerpen.be/en/about-uantwerp/campuses/travel-info/>

ACCOMODATION

Via this link, participants are able to book rooms in Antwerp at a discount prices.

<https://antwerpconventionbureau.be/acb-antwerp-convention-bureau-antwerp/booking-desk/>.

There is no need to use an event code on the website, this is already incorporated in the link. When participants enter their arrival and departure date, available rooms will pop up with price per stay.

PROGRAM

Wednesday, August 30, 2023 - INTERCEPTOR DAY

11 AM - 12 AM

Registration and Check-in

12 AM - 1 PM

Lunch and Getting settled

1 PM - 1:30 PM

Welcome & objectives of the day

Pr. Pierre Saintigny - Chair (Centre Léon Bérard - FR)

Pr. Senada Koljenović - Vice Chair (Antwerp University Hospital - BE)

1:30 PM - 3:30 PM

Concurrent Working Group sessions

Breakout session room 1 : Working Groups 1/6/7

Breakout session room 2 : Working Groups 2/3

Breakout session room 3 : Working Groups 4/5

3:30 PM - 4 PM

Coffee break



Picture!

4 PM - 6 PM

Management Committee meeting

7 PM -

Dinner

INTERCEPTOR

INTERCEPTION OF ORAL CANCER DEVELOPMENT

PROGRAM

Thursday, August 31, 2023 - OPMDAY

8: 30 AM - 9 AM

Registration and Check-in

9 AM - 9:15 AM

Welcome

Pr. Pierre Saintigny - Chair (Centre Léon Bérard - FR)
Pr. Senada Koljenović - Vice Chair (Antwerp University Hospital - BE)

9:15 AM - 9:45 AM

Keynote I : Novel therapeutic options for oral leukoplakia

Dr. Alessandro Villa (Miami Cancer Institute – US)

9:45 AM - 10:45 AM

Clinical & pathological diagnosis

Moderators: Pr. Rui Amaral Mendes - Pr. Senada Koljenović

Point-of-care Analysis for Non-invasive Diagnosis of Oral cancer (PANDORA)

Pr. Michael Hughes (Khalifa University, Abu Dhabi) (10+5 min)

The Histopathologic Challenges of Diagnosing Oral Premalignant Lesions

Pr. Mark Lingen (University of Chicago Medicine - US) (10+5 min)

Artificial intelligence for the clinical and pathological assessment of OPMD

Pr. Pierre Saintigny (Centre Léon Bérard - FR) (10+5 min)

Combination of Binary System with Ki67 Immunohistochemical Staining: a Reliable Grading Method for Oral Epithelial Dysplasia

Dr. Pouyan Aminshakib (School of Dentistry, Tehran University of Medical Sciences - IR) (10+5 min)

10:45 AM - 11 AM

Coffee break and Poster view

11 AM - 12 AM

Biomarkers and biological mechanisms

Moderators: Dr. Zisis Kozlakidis - Pr. Daniela Elena Costea

Building a patient cohort under FAIR principles

Dr. Myriam Merz (Charité-Universitätsmedizin Berlin – DE) (10+5 min)

The microbiota and oral cancer: from oncogenesis to treatment response

Dr. Miguel Reis Ferreira (Guys and St Tomas NHS Foundation Trust & King's College London - UK) (10+5 min)

Biomarkers indicating early malignancy in oral leukoplakia

Dr. Madara Dzudzilo (Department of Maxillo-Facial Surgery and Oral Medicine, Rīga Stradiņš University - LV) (10+5 min)

Investigation of the microbiome of oral leukoplakia (OLK)

Dr. Sheila Galvin (Dublin Dental University Hospital - IE) (10+5 min)

12 AM - 1 PM

Lunch Break and Poster view

PROGRAM

Thursday, August 31, 2023 - OPMDAY

1 PM - 1:30 PM

Keynote II : IARC Perspective on Oral Cancer Prevention

Pr. Saman Warnakulasuriya

(King's College London & WHO Collaborating Centre for Oral Cancer, London, UK)

1:30 PM - 2:30 PM

Disease management

Moderators: Mrs. Antonella Cardone - Pr. Merva Soluk Tekkeşin

OPMD management in Europe and Australia

Dr. Monica Pentenero (University of Torino - IT) (10+5 min)

Disease management from a patient perspective (10+5 min)

Mr. Rolf Erik Smith and Mr Jasper Stoop

Immune checkpoint inhibitor in high-risk oral potentially malignant disorders (IMPEDE study): an interim analysis on safety

Dr. Luigi Lorini (Humanitas Research Hospital - IT) (10+5 min)

VULA, an e-health medical /dental referral application

Dr. Haly Holmes (University of the Western Cape Dental Faculty - ZA) (10+5 min)

2:30 PM - 2:45 PM

Coffee break and Poster view



Picture!

2:45 PM - 3:45 PM

Introduction to set the stage for the round table: Patient's representatives; ethics and health-economics

3:45 PM - 4 PM

Coffee break and Poster view

4 PM - 4:15 PM

Award Ceremony

4:15 PM - 5:15 PM

INTERCEPTOR : Work in Progress

Moderators: Pr. Pierre Saintigny - Dr. Marine Benaissa

Embedding socio-economic and ethical aspects into clinical registries: exemples of relevance and impact on disease pathways

Pr. Rui Amaral Mendes (WG1 leader) / Dr. Valesca Retel (WG6 leader)

Defining clinical and pathological benchmarks and eHealth intervention and PROMs use in OPMD: the basis for trial design

Dr. Haly Holmes (WG3 leader) / Pr. Keith Hunter (WG2 co-leader) / Pr. Senada Koljenović (Vice-Chair)

Evaluation of research priorities on biobanking aspects for biological tissues from Oral Potentially Malignant Disorders

Dr. Moshe Elkabets (WG4 leader) / Dr. Zisis Kozlakidis (WG5 leader)

Communicating the COST Action INTERCEPTOR

Mrs. Antonella Cardone (WG7 leader)

5:15 PM - 5:30 PM

Closing remarks

SCIENTIFIC COMMITTEE

- Rui Amaral Mendes** Professor, Faculty of Medicine, University of Porto - MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences
Researcher at CINTESIS@RISE, Faculty of Medicine, University of Porto (Clinical and Translational Research in Oncology)
Adjunct Professor of Oral and Maxillofacial Medicine, Department of Oral and Maxillofacial Medicine and Diagnostic Sciences, Case Western Reserve University, Cleveland, OH, USA
- Marine Benaïssa** Science Communication Coordinator & INTERCEPTOR Project Manager, Department of Translational Medicine, Centre Léon Bérard, Lyon 69008, France
- Brenda Bogaert** Researcher in medical ethics -Institut des humanités en médecine UNIL-CHUV - Lausanne, Vaud, Switzerland
- Paolo Bossi** Associate Professor of Medical Oncology - Department of Biomedical Sciences – Humanitas University -Head of the Head and neck and non-melanoma skin cancer Oncology- Medical Oncology and Hematology Unit - Humanitas Cancer Center - IRCCS Humanitas Research Hospital
- Antonella Cardone** CEO of Cancer Patients Europe, the pan-European and all-cancer types patient association, Belgium
- Daniela Elena Costea** Professor, Gade Laboratory for Pathology, Department of Clinical Medicine and Centre for Cancer Biomarkers CCBio, Haukeland University Hospital, University of Bergen, Norway
- Moshe Elkabets** Associate Professor at Ben-Gurion University. Research focus on development & therapy of head and neck cancer. Drug resistance, tumor microenvironment and immunity, Israel.
- Haly Holmes** Periodontist at University of the Western Cape. University of the Western Cape. City of Cape Town, Western Cape, South Africa
- Keith Hunter** Professor of Head and Neck Pathology, Liverpool Head and Neck Centre, Molecular and Clinical Cancer Medicine, University of Liverpool, United-Kingdom

SCIENTIFIC COMMITTEE

- Senada Koljenović** Professor and Head of Department of Pathology, Antwerp University Hospital/ University of Antwerp, Belgium
- Zisis Kozlakidis** Head of the Laboratory Services and Biobank Group (LSB) at IARC, WHO.
- Valesca Retèl** Head Health Technology Assessment (HTA) department, Netherlands Cancer Institute, Professor translational HTA - Erasmus University Rotterdam, The Netherlands
- Pierre Saintigny** Department of Medical Oncology, Centre Léon Bérard, Lyon, France ; Univ Lyon, Université Claude Bernard Lyon I, INSERM I052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69008, France.
- Dipak Sapkota** Professor, Department of Oral Biology, Faculty of Dentistry, University of Oslo, Norway
Academic editor of The Norwegian Dental Journal
- Merva Soluk Tekkeşin** Professor of Oral Pathology - Department of Tumour Pathology - Institute of Oncology, Istanbul University - 34093 Capa- Istanbul, Turkey

